Abbott (ABT) on Solana

Abbott Laboratories has agreed to pay $670 million to settle a high-profile lawsuit and related claims alleging that its cow's milk-based premature infant formula, Similac, causes necrotizing enterocolitis (NEC) — a severe intestinal disease in which tissue lining the intestine becomes inflamed and dies. The settlement resolves the case that produced a $495 million appellate judgment in 2026, including a Missouri jury award of $95 million in compensatory and $400 million in punitive damages on behalf of a premature infant who required removal of 75% of her intestine after developing NEC. Abbott admitted no liability and stated it "believes these agreements are in its best long-term interest."

Despite the settlement, Abbott's litigation exposure remains substantial: roughly 1,700 lawsuits covering approximately 12,700 infants are still pending nationwide. The company's CEO had previously floated the possibility of discontinuing the formula product entirely given the litigation volume, a prospect that alarmed physicians who rely on it for premature infants without access to breast milk. Government agencies including the FDA, CDC, and NIH stated in 2024 that there is no conclusive evidence that preterm infant formula causes NEC, though research shows associations between cow's milk formulas and elevated NEC rates. The $670 million payout adds meaningful near-term financial pressure while the broader docket remains unresolved.

Abbott and Alphabet announced a multi-year collaboration on August 11, 2026, integrating real-time data from Abbott's Lingo continuous glucose monitor into Google's Health app. Lingo is a non-prescription CGM biowearable that tracks metabolic data—blood glucose, nutrition response, sleep, and recovery—without a doctor's prescription, positioning it at the consumer wellness end of Abbott's diabetes care portfolio. Under the partnership, Lingo data feeds into Google's AI Health Coach, which then surfaces personalized guidance tied to a user's actual biometric readings rather than generic population averages.

The deal extends Abbott's digital health ambitions beyond the clinical market it dominates with FreeStyle Libre, tapping Google's consumer reach and AI infrastructure to drive Lingo adoption at scale. Abbott's Diabetes Care segment reported 10.5% revenue growth in Q2 2026, contributing to company-wide quarterly sales of $12.59 billion—up 13% year-over-year. Pairing Lingo's real-time metabolic data with a widely used health platform could accelerate the consumer CGM category while giving Abbott a direct channel into preventive health management, where recurring device usage and subscription-adjacent engagement models represent meaningful long-term revenue opportunities.

Abbott Laboratories completed a share repurchase program totaling approximately $1.35 billion, with 14,015,097 shares acquired in total and 11,599,094 of those purchased between April and June 2026. A Simply Wall St valuation analysis places ABT's fair value at $119.13 per share against a closing price of $107.81, implying the stock could be roughly 10% undervalued. The model weighs revenue growth, margin expansion, and product-mix improvement, with emerging market expansion across India, China, Latin America, and the Middle East — alongside biosimilar launches — underpinning expectations of continued double-digit top-line growth.

Despite a strong 90-day gain of nearly 28%, Abbott shares remain down about 13% year-to-date, weighed in part by the April acquisition of Exact Sciences in a $23 billion deal that initially diluted near-term guidance. Analysts note ongoing pricing pressure in diagnostics and glucose monitoring, along with tariff and foreign exchange headwinds, as key risks to the valuation case. For shareholders, the completed buyback signals management's view that ABT is attractively priced, while the Exact Sciences integration and emerging-market pipeline position the company for longer-term earnings growth.

A federal judge dismissed a securities fraud lawsuit against Abbott Laboratories on July 24, 2026, stemming from the company's February 2022 recall of powdered infant formula products — Similac, Alimentum, and EleCare — manufactured at its Sturgis, Michigan facility. U.S. District Judge Steven Seeger of the Northern District of Illinois ruled that shareholders, led by two European asset managers, failed to demonstrate that Abbott intended to deceive investors or artificially inflate its stock price, writing that "Mismanaging a plant that makes infant formula is bad. But it's not securities fraud."

Shareholders had alleged Abbott delayed disclosing bacterial contamination to regulators, concealed poor plant conditions, and made false statements about regulatory compliance. Abbott held more than 40% of the U.S. infant formula market before the recall, which contributed to a national formula shortage. The court found the claims insufficient and indicated that amending the complaint would likely be futile.

Abbott disclosed on July 17, 2026 that it is investigating two separate cyber incidents involving unauthorized access to internal systems. The first affected internal systems within its cancer diagnostics business, while the second involved the LabCentral portal, a third-party-hosted, externally facing platform used by its core laboratory diagnostics unit. Abbott said it has engaged outside cybersecurity experts and law enforcement and that no other businesses, sites, or systems were impacted by either incident.

The company stated that operations were not affected and that it does not expect any material impact on its business or financial results. On the LabCentral breach, Abbott noted that the portal contained only publicly available technical documents such as manuals, troubleshooting guides, and product specifications, with no known exposure of sensitive customer or business information. The disclosures come amid a broader wave of cyberattacks targeting healthcare companies across the industry.

Abbott shares rallied after the company reported second-quarter sales of $12.6 billion, up 13% year-over-year, and adjusted earnings per share of $1.31 — beating analyst expectations of $1.28. Diagnostics was the standout segment, with sales surging 42.3% to $3.1 billion, driven in large part by Abbott's $21 billion acquisition of Exact Sciences in March, which added the Cologuard colorectal cancer screening test to its portfolio. Medical devices grew 9% to $5.9 billion, with continuous glucose monitor sales rising 11%.

Management raised its full-year adjusted EPS outlook to a range of $5.45–$5.60, up from a prior forecast of $5.38–$5.58, and guided full-year comparable sales growth of 6.5%–7.5% for 2026. The stronger-than-expected results also reinforce Abbott's position as a dividend compounder — the company has raised its dividend for 54 consecutive years.

Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target, citing the company's diversified portfolio as a foundation for steady top-line and earnings growth over the next several years. The firm's thesis centers on Abbott's medical devices segment, which it views as positioned for above-peer performance, supported by new product launches and expanding indication opportunities expected to provide a clearer upside path into fiscal 2027-2028.

Abbott's business spans medical devices, diagnostics, nutrition, and established pharmaceuticals. Baird pointed to healthy procedure volumes and favorable capital expenditure trends across the MedTech and diagnostics sectors as near-term tailwinds supporting the outlook.

Abbott's FreeStyle Libre 3 Plus continuous glucose monitor (CGM) has gained a new major ecosystem integration, with Tandem Diabetes Care's t:slim X2 insulin pump using Control-IQ+ closed-loop technology now compatible with the sensor across five European countries. The partnership expands the reach of Abbott's flagship CGM in Europe by connecting it with one of the region's leading automated insulin delivery platforms, deepening the Libre 3 Plus footprint in the fast-growing diabetes technology market.

The integration represents a complementary pairing rather than a competitive overlap, as Abbott's CGM feeds glucose data directly into Tandem's pump algorithm. For Abbott's diabetes care segment, broader device ecosystem compatibility has historically supported sensor attachment rates and recurring sensor revenue, as patients paired with compatible pump platforms tend toward consistent CGM use.

A federal judge has ruled that a proposed class-action lawsuit against Abbott Laboratories over its PediaSure Grow & Gain nutritional drink can proceed, rejecting the company's bid for dismissal. U.S. District Judge Paul Engelmayer issued a 75-page decision on June 4 finding that jurors could reasonably interpret Abbott's marketing — including the product name, giraffe-and-ruler branding, and commercials depicting a child comparing his height to taller peers — as a specific promise of height growth. Plaintiff Joanne Noriega alleged her grandson drank PediaSure daily for a year without gaining height, instead becoming overweight, after she relied on the "clinically proven" language on the label.

Abbott maintains its labeling is "appropriate" and that the product does support children's growth and development. With the misrepresentation claims now surviving the dismissal stage, the case moves toward potential class certification and trial, raising the prospect of significant consumer-restitution exposure tied to Abbott's Nutritional Products segment, which markets PediaSure as one of its flagship brands.

Abbott Laboratories (ABT) has gained roughly 6.5% over the past week and 9.9% over the past month, yet the stock remains down about 24% year-to-date and 28.5% over the past year. Despite the rebound, a valuation analysis published via Simply Wall St on Yahoo Finance scores Abbott 5 out of 6 on undervaluation checks, with both a discounted cash flow model and a price-to-earnings comparison pointing to the stock trading below fair value. The DCF model estimates intrinsic value at $141.15 per share — implying a roughly 33% discount at current prices — based on trailing twelve-month free cash flow of approximately $7.1 billion and a projected rise to $10.4 billion by 2028.

On a P/E basis, Abbott trades at 26.22x, roughly in line with the medical equipment industry average of 26.15x but meaningfully below the peer group average of 31.58x and below Simply Wall St's own fair ratio estimate of 30.25x. Community-sourced fair value estimates on the platform span a wide range of approximately $92 to $135 per share, reflecting diverging assumptions about Abbott's growth trajectory, which the analysis links to narratives around the company's cancer diagnostics expansion and its dividend track record.